JP2018538246A - Ａｃｃ阻害剤およびその使用 - Google Patents

Ａｃｃ阻害剤およびその使用 Download PDF

Info

Publication number
JP2018538246A
JP2018538246A JP2018521087A JP2018521087A JP2018538246A JP 2018538246 A JP2018538246 A JP 2018538246A JP 2018521087 A JP2018521087 A JP 2018521087A JP 2018521087 A JP2018521087 A JP 2018521087A JP 2018538246 A JP2018538246 A JP 2018538246A
Authority
JP
Japan
Prior art keywords
grams
membered
ring
independently selected
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018521087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538246A5 (enExample
Inventor
ショミール ゴーシュ，
ショミール ゴーシュ，
ジェラルディン シー． ハリマン，
ジェラルディン シー． ハリマン，
デ モラデイ， シルヴァーナ マルセル レイト
デ モラデイ， シルヴァーナ マルセル レイト
ジェレミー アール． グリーンウッド，
ジェレミー アール． グリーンウッド，
Original Assignee
ギリアド アポロ， エルエルシー
ギリアド アポロ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアド アポロ， エルエルシー, ギリアド アポロ， エルエルシー filed Critical ギリアド アポロ， エルエルシー
Publication of JP2018538246A publication Critical patent/JP2018538246A/ja
Publication of JP2018538246A5 publication Critical patent/JP2018538246A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pest Control & Pesticides (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
JP2018521087A 2015-10-26 2016-10-26 Ａｃｃ阻害剤およびその使用 Pending JP2018538246A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562246318P 2015-10-26 2015-10-26
US62/246,318 2015-10-26
PCT/US2016/058867 WO2017075056A1 (en) 2015-10-26 2016-10-26 Acc inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2018538246A true JP2018538246A (ja) 2018-12-27
JP2018538246A5 JP2018538246A5 (enExample) 2019-12-05

Family

ID=57233943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018521087A Pending JP2018538246A (ja) 2015-10-26 2016-10-26 Ａｃｃ阻害剤およびその使用

Country Status (14)

Country Link
US (2) US10179793B2 (enExample)
EP (1) EP3368540A1 (enExample)
JP (1) JP2018538246A (enExample)
KR (1) KR20180067603A (enExample)
CN (1) CN108368125A (enExample)
AR (1) AR106472A1 (enExample)
AU (1) AU2016344392A1 (enExample)
BR (1) BR112018008227A2 (enExample)
CA (1) CA3003275A1 (enExample)
EA (1) EA201890749A1 (enExample)
IL (1) IL258636A (enExample)
MX (1) MX2018005292A (enExample)
SG (1) SG11201802989QA (enExample)
WO (1) WO2017075056A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021112213A1 (ja) * 2019-12-05 2021-06-10 日本曹達株式会社 ２，４－ジオキソ－１，４－ジヒドロチエノピリミジン化合物、及びそれを含有する農園芸用殺菌剤又は医療用・動物用抗真菌剤
JP2022551014A (ja) * 2019-12-05 2022-12-06 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 Ａｃｃ１及びａｃｃ２阻害剤としての結晶形及びその製造方法並びに使用

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370976B (es) 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
CN107207444B (zh) 2014-11-26 2020-07-24 武田药品工业株式会社 二环化合物
PL3380479T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
EP3380478B1 (en) 2015-11-25 2020-12-23 Gilead Apollo, LLC Ester acc inhibitors and uses thereof
US20170166582A1 (en) 2015-11-25 2017-06-15 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
CN108347939B (zh) 2015-11-25 2021-09-28 吉利德阿波罗公司 含有2,4-二氧代-1,4-二氢噻吩并[2,3-d]嘧啶的衍生物的杀真菌组合物
CA3155220C (en) * 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
SG11201902588PA (en) 2016-09-23 2019-05-30 Bayer Ag N3-Cyclically Substituted Thienouracils And Use Thereof
AU2018209006B2 (en) 2017-01-22 2021-04-22 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
EP3589635A1 (en) * 2017-03-03 2020-01-08 Gilead Apollo, LLC Processes for the preparation of fungicidal compounds
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
WO2018228369A1 (zh) * 2017-06-15 2018-12-20 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途
EP3660023B1 (en) * 2017-07-26 2023-03-08 Nanjing Sanhome Pharmaceutical Co., Ltd. Thienopyrimidinedione compounds as acc inhibitors and use thereof
US10584133B2 (en) 2018-03-30 2020-03-10 Biotheryx, Inc. Thienopyrimidinone compounds
CN112218871B (zh) * 2018-06-05 2022-10-18 南京明德新药研发有限公司 噻吩并[2,3-c]哒嗪-4(1H)-酮类衍生物及其应用
CN113613495B (zh) * 2018-11-02 2023-05-23 美国陶氏益农公司 包含氟氯吡啶酸和其他除草剂的组合物及其方法
AU2019385438A1 (en) * 2018-11-20 2021-05-27 The National Institutes of Pharmaceutical R&D Co., Ltd. Spiro compound and medical uses thereof
CN111484504B (zh) * 2019-01-25 2024-05-10 南京圣和药业股份有限公司 Acc抑制剂的光学异构体及其应用
US20220152164A1 (en) * 2019-03-22 2022-05-19 Kallyope, Inc. Gpcr combination therapies
CN113924303B (zh) 2019-07-02 2023-10-20 广东东阳光药业股份有限公司 具有立体构型的噻吩并嘧啶衍生物及其在药物中的应用
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CN110746439B (zh) * 2019-10-18 2020-10-30 南京瑞捷医药科技有限公司 一种噻吩并嘧啶二酮化合物的制备方法
CN114787166B (zh) * 2019-12-05 2023-09-19 漳州片仔癀药业股份有限公司 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用
MX2022012677A (es) * 2020-04-08 2023-01-11 Remix Therapeutics Inc Compuestos y metodos para modular el empalme.
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN113968871A (zh) * 2020-07-25 2022-01-25 南京圣和药业股份有限公司 苯基取代类acc抑制剂的晶型
WO2022133097A1 (en) * 2020-12-17 2022-06-23 Biogen Ma Inc. Synthesis of compounds that modulate use-dependent voltage-gated sodium channels
WO2022138812A1 (ja) 2020-12-24 2022-06-30 モジュラス株式会社 テトラヒドロチエノピリミジンスルホンアミド化合物
WO2022268520A1 (de) * 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.
CN115677551A (zh) * 2021-12-28 2023-02-03 武汉市振邦生物科技有限公司 一种2-氧代吡咯烷-3-甲酸乙酯的制备工艺
CR20250040A (es) 2022-08-05 2025-03-18 Gilead Sciences Inc Inhibidores de la proteasa principal de sars-cov2
CN115433756B (zh) * 2022-08-30 2024-04-09 山东新华制药股份有限公司 一种泼尼松龙的制备方法
US20250276979A1 (en) * 2024-02-07 2025-09-04 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62289583A (ja) * 1986-04-28 1987-12-16 オ−ソ・フア−マシユ−チカル・コ−ポレ−シヨン チエノピリミジン−２，４−ジオン誘導体類およびそれらの中間生成物類
US4835157A (en) * 1988-03-15 1989-05-30 Ortho Pharmaceutical Corporation Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents
JPH0761986A (ja) * 1990-02-22 1995-03-07 Takeda Chem Ind Ltd 縮合チオフェン誘導体
US6166019A (en) * 1998-07-16 2000-12-26 Abbott Laboratories Piperazinyl pyrimidine dione compounds selective for adrenoceptors
JP2003292492A (ja) * 2002-01-30 2003-10-15 Takeda Chem Ind Ltd チエノピリミジン化合物、その製造法および用途
JP2004518732A (ja) * 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’２，３−ｄピリミジンジオン誘導体
WO2008143262A1 (ja) * 2007-05-21 2008-11-27 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
JP2014533281A (ja) * 2011-11-11 2014-12-11 ニンバス アポロ， インコーポレイテッド Ａｃｃ阻害剤およびその使用
WO2015007451A1 (en) * 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02225485A (ja) 1989-02-27 1990-09-07 Taiho Yakuhin Kogyo Kk チエノピリミジン―３―酢酸誘導体
JP3811196B2 (ja) 1993-08-26 2006-08-16 武田薬品工業株式会社 エンドセリン拮抗剤、チエノピリミジン誘導体およびその製造法
TW276256B (enExample) 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
WO2000061583A1 (en) 1995-06-07 2000-10-19 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signaling inhibitors
AU6670196A (en) 1995-08-17 1997-03-12 Takeda Chemical Industries Ltd. Thienopyrimidine derivatives, their production and use
JPH09110873A (ja) 1995-08-17 1997-04-28 Takeda Chem Ind Ltd チエノピリミジン誘導体、その製造法および用途
JP2007302703A (ja) 1996-04-30 2007-11-22 Takeda Chem Ind Ltd 医薬組成物
AU2407997A (en) 1996-04-30 1997-11-19 Takeda Chemical Industries Ltd. Combined use of gnrh agonist and antagonist
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6984644B2 (en) 1997-05-28 2006-01-10 Astrazeneca Ab Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
DE19754082A1 (de) 1997-12-05 1999-06-10 Knoll Ag Methode zur Bekämpfung der Fettleibigkeit
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
WO2003072197A1 (en) 2002-02-27 2003-09-04 Pfizer Products Inc. Acc inhibitors
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
ES2324472T3 (es) 2003-01-06 2009-08-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Herbicidas que inhiben la accion de acetil-coa carboxilasa en vegetales para su uso como pesticidas.
CN101153042A (zh) 2003-01-29 2008-04-02 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
WO2006014647A2 (en) 2004-07-21 2006-02-09 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
CA2644996A1 (en) 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
PT2519527E (pt) 2009-12-29 2014-02-17 Poxel Tieno[2,3-b]piridinodiona como activadores de ampk e suas utilizações terapêuticas
AU2011252874A1 (en) * 2010-05-14 2012-11-29 University Of Rochester Compositions and methods for targeting A3G:RNA complexes
EP2994128B1 (en) 2013-05-10 2019-01-30 Gilead Apollo, LLC Acc inhibitors and uses thereof
AU2014262638A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
EA201591962A1 (ru) 2013-05-10 2016-06-30 Нимбус Аполло, Инк. Ингибиторы акк и их применение
AU2014262636A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
TWI652012B (zh) 2013-05-20 2019-03-01 杜邦股份有限公司 殺真菌吡唑的固態形式
WO2015007453A1 (en) * 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
CN108347939B (zh) 2015-11-25 2021-09-28 吉利德阿波罗公司 含有2,4-二氧代-1,4-二氢噻吩并[2,3-d]嘧啶的衍生物的杀真菌组合物
EP3380478B1 (en) 2015-11-25 2020-12-23 Gilead Apollo, LLC Ester acc inhibitors and uses thereof
PL3380479T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
US20170166582A1 (en) 2015-11-25 2017-06-15 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62289583A (ja) * 1986-04-28 1987-12-16 オ−ソ・フア−マシユ−チカル・コ−ポレ−シヨン チエノピリミジン−２，４−ジオン誘導体類およびそれらの中間生成物類
US4835157A (en) * 1988-03-15 1989-05-30 Ortho Pharmaceutical Corporation Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents
JPH0761986A (ja) * 1990-02-22 1995-03-07 Takeda Chem Ind Ltd 縮合チオフェン誘導体
US6166019A (en) * 1998-07-16 2000-12-26 Abbott Laboratories Piperazinyl pyrimidine dione compounds selective for adrenoceptors
JP2004518732A (ja) * 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’２，３−ｄピリミジンジオン誘導体
JP2003292492A (ja) * 2002-01-30 2003-10-15 Takeda Chem Ind Ltd チエノピリミジン化合物、その製造法および用途
WO2008143262A1 (ja) * 2007-05-21 2008-11-27 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
JP2014533281A (ja) * 2011-11-11 2014-12-11 ニンバス アポロ， インコーポレイテッド Ａｃｃ阻害剤およびその使用
WO2015007451A1 (en) * 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021112213A1 (ja) * 2019-12-05 2021-06-10 日本曹達株式会社 ２，４－ジオキソ－１，４－ジヒドロチエノピリミジン化合物、及びそれを含有する農園芸用殺菌剤又は医療用・動物用抗真菌剤
JP2022551014A (ja) * 2019-12-05 2022-12-06 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 Ａｃｃ１及びａｃｃ２阻害剤としての結晶形及びその製造方法並びに使用
JP7265681B2 (ja) 2019-12-05 2023-04-26 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 Ａｃｃ１及びａｃｃ２阻害剤としての結晶形及びその製造方法並びに使用

Also Published As

Publication number Publication date
MX2018005292A (es) 2018-08-01
BR112018008227A2 (pt) 2018-10-23
AR106472A1 (es) 2018-01-17
US20190330224A1 (en) 2019-10-31
SG11201802989QA (en) 2018-05-30
US10179793B2 (en) 2019-01-15
US20170145028A1 (en) 2017-05-25
WO2017075056A1 (en) 2017-05-04
AU2016344392A1 (en) 2018-05-10
EA201890749A1 (ru) 2018-11-30
CN108368125A (zh) 2018-08-03
EP3368540A1 (en) 2018-09-05
CA3003275A1 (en) 2017-05-04
IL258636A (en) 2018-06-28
KR20180067603A (ko) 2018-06-20

Similar Documents

Publication Publication Date Title
US10179793B2 (en) ACC inhibitors and uses thereof
US10800791B2 (en) Triazole ACC inhibitors and uses thereof
US10941158B2 (en) Pyrazole ACC inhibitors and uses thereof
US11098055B2 (en) Ester ACC inhibitors and uses thereof
US10472374B2 (en) ACC inhibitors and uses thereof
HK1255652A1 (en) Acc inhibitors and uses thereof
HK1255652B (en) Acc inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191024

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210506